



Maharaft

Sodium Alginate 250 mg, Sodium Bicarbonate 133.5 mg and
Calcium Carbonate 80 mg Oral Suspension



Mint
Flavour

Maharaft


Sodium Alginate 250 mg, Sodium Bicarbonate 133.5 mg and Calcium Carbonate 80 mg Oral Suspension

Background:

Gastroesophageal reflux disease (GERD) is a common gastrointestinal (GI) ailment that affects around 7.6% to 30% of the population in India¹ and heartburn is a primary symptom of gastroesophageal reflux disease (GERD).

The main therapeutic approach to the management of heartburn is to decrease esophageal acid exposure by neutralizing gastric acid and alginate-containing antacids have been used for the symptomatic treatment of heartburn and esophagitis for over 30 years.²

Alginate raft structure formation following ingestion of an alginate-containing formulation³:



A. Alginates react with the stomach acid to form a gel-like substance with neutral pH.

B. Sodium bicarbonate contained in the formulation releases carbon dioxide gas, which becomes trapped in the gel. The trapped carbon dioxide gas allows the gel to float to the surface of the stomach content.

C. Effectively forming a raft structure that acts as a barrier over the gastric acid pocket, and blocks against upward reflux.

RANDOMISED CLINICAL TRIAL: ADDITION OF ALGINATE-ANTACID ORAL SUSPENSION TO PROTON PUMP INHIBITOR THERAPY IN PATIENTS WITH BREAKTHROUGH SYMPTOMS

Aliment Pharmacol Ther. 2017;45:1524–1533.


No. of Patients:

⚡ **Exploratory study** (Alginate-Antacid Group(N)= 26, Placebo (N)=26)

⚡ **Confirmatory study** (Alginate-Antacid Group(N)= 131, Placebo (N)=131)

Duration: 7-9 days treatment period

Dose: 20 ml of suspension four times a day (30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before going to bed) with PPI.



Conclusion:

In Post hoc “responder” analysis of the exploratory study significantly more Alginate-Antacid patients (75%) achieved ≥ 3 days reduction in “bad” days vs placebo patients (36%).

RANDOMIZED CLINICAL TRIAL: SODIUM ALGINATE ORAL SUSPENSION IS NON-INFERIOR TO OMEPRAZOLE IN THE TREATMENT OF PATIENTS WITH NON-EROSIVE GASTROESOPHAGEAL DISEASE

Aliment Pharmacol Ther 2013; 38: 1054–1064

No of Patients: 195 NERD Patients (Sodium Alginate (n=97); Omeprazole Group (n=98))

Duration of study: 4 weeks

Dose: Sodium alginate suspension 20 ml three times a day and omeprazole 20 mg once daily.

Result:

⚡ 41.7% of subjects in the sodium alginate group vs. 39.8% of subjects in the omeprazole group achieved complete relief after 4 weeks of treatment.

⚡ Symptom improvement defined as a decrease in symptom score at day 28 compared with baseline is 98.8% (83/84) in the alginate group and 96.6% (85/88) in the omeprazole group.

Conclusion: Sodium alginate is as effective as omeprazole for symptomatic relief in patients with non-erosive reflux disease.

Maharaft[®]

Sodium Alginate 250 mg, Sodium Bicarbonate 133.5 mg and Calcium Carbonate 80 mg Oral Suspension

Description:

Maharaft[®] Mint Oral Suspension 150 ml contains Sodium Alginate 250 mg, Sodium Bicarbonate 133.5 mg, and Calcium Carbonate 80 mg. The alginate-antacid formulation co-localize and eliminate the acid pocket in GERD.

Indication:

Maharaft[®] is indicated in the treatment of Gastroesophageal Reflux Disease (GERD), Acid Reflux, Indigestion, Heartburn, Acidity, Gas

Mechanism of Action:



Antacid

- 01 Neutralises acid for indigestion relief



Alginate

- 02 Creates a protective reflux barrier



Antacid-alginate combination products

- 03 The antacid neutralises acid for indigestion relief
04 The alginate forms a protective 'raft' to help prevent reflux

Key Benefits:

- Sodium alginate's unique non-systemic mechanism of action provides rapid and long-duration relief of heartburn and acid reflux symptoms.²
- The alginate raft provides sufficient viscosity to reduce reflux episodes.²
- Combination of two antacids and alginate
- Comes in a refreshing mint flavour
- Sugar-free Oral Suspension
- Caco3 rapidly neutralize esophageal pH when swallowed as liquid.⁴

Dosage:

10-20 ml after meals and at bedtime (Up to 4 times a day) or as directed by the Physician.

Storage:

Store at a temperature not exceeding 30°C.

Presentation:

Maharaft[®] Oral Suspension is available in 150 ml of a glass bottle.

References:

1. Indian Society of Gastroenterology 2019 | 2. Aliment Pharmacol Ther 2000; 14: 669-690 | 3. Ali et al. BMC Gastroenterology (2022) 22:219 | 4. Digestive Diseases and Sciences, Vol. 49, Nos. 11/12

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

I am: _____
Call me on: _____
Mail me at: _____